| November/December 201810

Retrospective

Nov. 25, 2013

Olysio approved as hepatitis C treatment

The FDA has approved Olysio (simeprevir, Janssen) as part of an anti-viral treatment regimen with pegylated interferon and ribavirin for the treatment of patients with chronic hepatitis C genotype 1.

Dec. 6, 2013

FDA approves once-daily oral Sovaldi as hepati-tis C treatment

The FDA today ap-proved once-daily oral nucleotide analog Sovaldi (sofosbuvir, Gilead Sciences) as part of an antiviral regi-men for the treatment of hepatitis C patients with genotypes 1, 2, 3 or 4, according to a news release.

Oct. 10, 2014

FDA approves Harvoni for HCV treatment

Using the breakthrough therapy designation, the FDA approved the first combination

pill for treatment of chronic hepati-tis C virus geno-type 1 that does not require inter-feron or ribavirin for administration, according to an agency release.

2013

Healio.com/HCV

VOL 1 • NO 1January/February 2014

The Promise of NEW HCV

THERAPIES Your Guide to the Age

After Interferon

FEATUREInside the new

AASLD/IDSA/IAS-USA guidelines

PATIENT PROFILE HCV and Pregnancy

THE TAKE HOME The Liver Meeting

2013

5 QUESTIONS A Conversation with

Eric J. Lawitz, MD

Healio.com/HCV

VOL 1 • NO 2March/April 2014

FEATURECalling All Baby Boomers:

HCV Screening Slowly Takes Hold

PATIENT PROFILE Current Concepts on HCV

and Cryoglobulinemia

THE TAKE HOME CROI 2014

5 QUESTIONS A Conversation with

Douglas T. Dieterich, MD

THE PRICE OF A CUREDAA is $1,000 a pill; SVR is priceless.

HCV Next in Retrospect:Looking Back at ‘Your Guide to the Age After Interferon’

2014

Healio.com/HCV

VOL 1 • NO 4July/August 2014

FEATURE Treat Now or Wait

PATIENT PROFILE Insulin Resistance, NAFLD and HCV

THE BIG PICTURE HCV and HIV: Different Viruses,

Striking Similarities

5 QUESTIONS A Conversation with Nancy S. Reau, MD

Millennials, Drugs and HCV

A surge in injection drug use is shifting the

epidemiology of HCV.

Healio.com/HCV 11

Retrospective

Dec. 19, 2014

FDA approves Viekira Pak for treatment of HCV

The FDA today approved a treatment for patients with hepatitis C virus genotype 1 infection, including those with cirrhosis, according to a press release.

Jul. 24, 2015

FDA approves Da-klinza for chronic hepatitis C geno-type 3 infections

FDA approves Daklinza for chronic hepatitis C genotype 3 infections

Healio.com/HCV

VOL 2 • NO 6June 2015

HCV AT A CROSSROADS: The Pre- or Post-Transplant Treatment Debate

THE TAKE HOMEInternational Liver Congress 2015

PATIENT PROFILEHepatitis C and End Stage Renal Disease

5 QUESTIONSA Conversation with Eric M. Yoshida, MD

PATIENT PROFILEThe Impact of NAFLD on Chronic HCV Progression, Treatment Response

FEATUREHCV Genotype 4: A Global Challenge

5 QUESTIONS A Conversation with Andrea L. Cox, MD, PhD

Healio.com/HCV

VOL 2 • NO 5May 2015

Business is Booming:WEIGHING THE WISDOMof Expanded HCV Screening

2015

Healio.com/HCV

VOL 2 • NO 3March 2015

FEATUREThe Dangers of HCV Transmission: How the Infection Spreads Today

PEDIATRIC HCVSetting Things Straight: How To Counsel Parents of HCV-Infected Children

HCV RXTargeting the HCV Genome: A Four-Drug Fixed-Dose Regimen

5 QUESTIONS A Conversation with Andrew J. Muir, MD, MHS

Breaking the 12-Week

BARRIERThe Search for Shorter Treatment Duration in HCV Therapy

“ Combination therapy aimed at multiple viral and host targets could lead to effective and short duration therapy. ... If such regimens were safe, well tolerated and affordable, that would be an important step in achieving global HCV eradication.”William Sievert, MD

FEATURECVD Prevention, Treatment Challenging as Patients With HCV, HIV Live Longer

MEETING NEWS COVERAGEDigestive Disease Week

5 QUESTIONSA Conversation with Catherine T. Frenette, MD

HCV IN MSM:An Epidemic With a ‘Shocking’ Lack of Education

Healio.com/HCV

VOL 2 • NO 7July 2015

“ Making hepatitis C a disease of the past comes with a price, but it will save lives and money in the long term.”John Ward, MD

| November/December 201812

Retrospective

2015 2016 2017

Healio.com/HCV

VOL 2 • NO 11November 2015

PATIENT PROFILEPatient-Centered Medical Homes:

The Next Wave of HCV Care

EDITORIALFree Market Still Hidden from

Physician, Patient View

5 QUESTIONS A Conversation with Phillip O. Coffin, MD

PRICING PRESSURES:How the Business of Medicine

Affects the Price of Therapy

Jun. 28, 2016

FDA approves Epclusa for all HCV geno-types

The FDA announced it has approved Epclusa for the treatment of all chronic hepatitis C virus genotypes in adults with and without cirrhosis. For patients with moderate to severe cirrhosis, it is approved in combination with ribavirin.

July 18, 2017

FDA approves Vosevi for HCV

FDA announced the approval of Vosevi for the treatment of adults with chronic hepatitis C genotypes 1 through 6, ac-cording to an agency press release.

April 7, 2017

FDA approves Sovaldi, Harvoni for pediatric patients with HCV

The FDA has approved Sovaldi and Harvoni as supplemental ap-plications for the treatment of hepatitis C in children aged 12 to 17 years, according to an FDA news release.

“ The failure rate of these drugs is 3%. ... The risk of dying on the waiting list is greater than that. It is certainly not an ethical issue in terms of risk–benefit.”Robert S. Brown Jr., MD, MPH

Healio.com/HCV

VOL 4 • NO 4April 2017

TREND WATCHFDA Approves DAAs for

Pediatric Patients with HCV

HCV-Positive, Recipient-NegativeTransplant Solves Problems, Raises Questions

Healio.com/HCV

VOL 4 • NO 6July/August 2017

EDITORIAL Universal Screening is

a Pathway to Eradication

FEATURETargeting MSM with HIV: Treatment as Prevention

in the Netherlands

Facing the Challenges of Universal Screening

for HCV

Healio.com/HCV 13

Retrospective

2018

Healio.com/HCV

VOL 4 • NO 7September/October 2017

HIV/HCV CoinfectionRemains Marginalized

Despite Progress

EDITORIAL Two Approvals Offer Even More Options for HCV Treatment

MEETING NEWS World Indigenous

People’s Conference on Viral Hepatitis

Healio.com/HCV

VOL 5 • NO 5September/October 2018

AASLD INVESTS $4 MILLION IN LIVER DISEASE

RESEARCH, DEVELOPMENT

HCV-Positive Organs:A Viable Optionfor UninfectedTransplant Patients

Healio.com/HCV

VOL 5 • NO 2March/April 2018

EDITORIAL Moving Beyond the Low-Hanging Fruit in HCV Diagnosis and Treatment

FEATUREPharmacist Collaboration in HCV, HIV Extends the Reach of Care

TREND WATCH Organizations Push Congress to Award $100 Million for Outbreaks

Treating People Who Inject Drugs:How to Reach a Difficult-to-Engage Population

August 3, 2017

FDA approves Mavyret, the first pan-genotypic 8-week treatment for HCV

The FDA approved AbbVie’s Mavyret to treat adults with hepatitis C genotypes 1 through 6 without cirrhosis or with mild cirrhosis, including those who failed previous direct-acting antiviral treatment, ac-cording to an agency press release. The new approval indicates only 8 weeks of treatment needed in treatment-naive patients without cirrhosis.

“ The opioid epidemic in the United States has led to an increased recognition and realization that HCV is not a finished issue.”Andrew H. Talal, MD, MPH

Healio.com/HCV

VOL 4 • NO 8November/December 2017

Welcome to the New World Order:

A Competitive HCV Drug Marketplace

THE LIVER MEETING Surgeon General: We Will Conquer

HCV, Opioids ‘One Bite at a Time’

TREND WATCH Cost, Fear of Side Effects Key

Barriers to HCV Treatment

“ My patients are fearful and angry that they are being denied hepatitis C treatment.”Vincent Lo Re III, MD, MSCE